This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01732458
First received: November 19, 2012
Last updated: November 24, 2016
Last verified: November 2016
  Purpose
The purpose of this study is to determine the appropriate dosing regimen of aprepitant for the prevention of post-operative nausea and vomiting in pediatric participants birth to 17 years.

Condition Intervention Phase
Post-Operative Nausea Post-Operative Vomiting Drug: Aprepitant Drug: Placebo to match aprepitant Drug: Ondansetron Drug: Placebo to match ondansetron Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator- Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Maximum (peak) plasma drug concentration (Cmax) [ Time Frame: Day 1 ]
  • Time to maximum observed plasma concentration (Tmax) [ Time Frame: Day 1 ]
  • Area under the concentration-time curve from time zero to infinity (AUC[0-∞]) [ Time Frame: Day 1 ]
  • Apparent total clearance of the drug from plasma after oral administration (CL/F) [ Time Frame: Day 1 ]
  • Aprepitant Terminal Phase Half-Life (t1/2) [ Time Frame: Day 1 ]

Enrollment: 229
Study Start Date: February 2013
Study Completion Date: September 2016
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aprepitant Dose 1

Dosing will be based on age and weight. The dose given will be the adult equivalent of 125 mg aprepitant.

A single dose of aprepitant (oral [PO]) and placebo matching ondansetron (intravenous [IV]) will be administered prior to induction of anesthesia.

Drug: Aprepitant
Other Names:
  • MK-0869
  • EMEND™
Drug: Placebo to match ondansetron
Experimental: Aprepitant Dose 2

Dosing will be based on age and weight. The dose given will be the adult equivalent of 40 mg aprepitant.

A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.

Drug: Aprepitant
Other Names:
  • MK-0869
  • EMEND™
Drug: Placebo to match ondansetron
Experimental: Aprepitant Dose 3

Dosing will be based on age and weight. The dose given will be the adult equivalent of 10 mg aprepitant.

A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.

Drug: Aprepitant
Other Names:
  • MK-0869
  • EMEND™
Drug: Placebo to match ondansetron
Experimental: Aprepitant Dose 4

Dosing will be based on age and weight. The dose given will be the adult equivalent of 2.5 mg aprepitant.

A single dose of aprepitant (PO) and placebo matching ondansetron (IV) will be administered prior to induction of anesthesia.

This dose will not be tested if submaximal efficacy is detected.

Drug: Aprepitant
Other Names:
  • MK-0869
  • EMEND™
Drug: Placebo to match ondansetron
Active Comparator: Ondansetron

4 mg for participants >40 kg in weight; 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron will be administered per the product label or based on local standard of care.

A single dose of ondansetron (IV) and placebo matching aprepitant (PO).

Drug: Placebo to match aprepitant Drug: Ondansetron
Other Name: Zofran

  Eligibility

Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant enrolled at birth should be at least 37 weeks gestation and ≥3 kg of weight
  • Scheduled to receive general anesthesia AND must have at least one of the following risk factors for post-operative nausea and vomiting (PONV) in addition to receiving general anesthesia:

    1. scheduled to have a surgery with an associated risk of PONV: tonsillectomy, adenoidectomy, strabismus surgery, dental surgery, hydrocelectomy, orchidopexy or herniorraphy; OR
    2. scheduled to have an operative procedure associated with PONV:

intraoperative opioid use or anticipated opioid administration within the first 24 hours following surgery.

Exclusion Criteria:

  • Emergency surgery for a life-threatening condition
  • Scheduled to receive propofol for maintenance of anesthesia (Note: propofol is permitted for induction of anesthesia).
  • Expected to receive opioid antagonists (e.g., naloxone, naltrexone) or

benzodiazepine antagonists (e.g., flumazenil)

  • Scheduled to undergo cardiac or neurosurgery
  • Vomiting caused by any organic etiology (such as gastric outlet

obstruction or small bowel obstruction)

  • Vomiting within 24 hours prior to surgery
  • Nasogastric or oral gastric tube intra- or post-operatively for suctioning

gastric contents

  • Active infection (e.g., pneumonia), congestive heart failure,

bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy, or a history of any illness which in the opinion of the investigator, might confound the results of the study or pose unwarranted risk to the participant

  • Use of any illicit drugs, including marijuana or has current evidence of alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01732458     History of Changes
Other Study ID Numbers: 0869-219
2011-006006-27 ( EudraCT Number )
Study First Received: November 19, 2012
Last Updated: November 24, 2016

Additional relevant MeSH terms:
Nausea
Vomiting
Postoperative Nausea and Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Postoperative Complications
Pathologic Processes
Ondansetron
Aprepitant
Fosaprepitant
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipruritics
Dermatologic Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents
Neurokinin-1 Receptor Antagonists

ClinicalTrials.gov processed this record on August 18, 2017